hybrid therapy (041ec1)

Hybrid therapy is a sequential-concomitant antibiotic regimen specifically developed for the eradication of Helicobacter pylori infection. The protocol typically spans 14 days and is divided into two distinct phases: a 7-day dual therapy phase consisting of a proton pump inhibitor (such as esomeprazole) and amoxicillin, followed by a 7-day quadruple therapy phase where metronidazole and clarithromycin are added to the initial dual regimen. This strategy is designed to maximize eradication rates by reducing bacterial load in the first phase and addressing potential antibiotic resistance in the second. Clinical studies, including those conducted by researchers like Antonio Mestrovic, have evaluated hybrid therapy as an alternative to standard triple or concomitant therapies, particularly in regions with high clarithromycin resistance.

Other names

hybrid regimensequential-concomitant therapy